Jaime L. Masferrer

21.3k total citations · 10 hit papers
135 papers, 17.9k citations indexed

About

Jaime L. Masferrer is a scholar working on Pharmacology, Genetics and Biochemistry. According to data from OpenAlex, Jaime L. Masferrer has authored 135 papers receiving a total of 17.9k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Pharmacology, 46 papers in Genetics and 33 papers in Biochemistry. Recurrent topics in Jaime L. Masferrer's work include Inflammatory mediators and NSAID effects (78 papers), Estrogen and related hormone effects (45 papers) and Eicosanoids and Hypertension Pharmacology (33 papers). Jaime L. Masferrer is often cited by papers focused on Inflammatory mediators and NSAID effects (78 papers), Estrogen and related hormone effects (45 papers) and Eicosanoids and Hypertension Pharmacology (33 papers). Jaime L. Masferrer collaborates with scholars based in United States, Spain and Chile. Jaime L. Masferrer's co-authors include Karen Seibert, Ben S. Zweifel, Alane Koki, Philip Needleman, K. Leahy, Peter C. Isakson, Scott D. Hauser, B. Mark Woerner, Mark G. Currie and Andrew J. Dannenberg and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Jaime L. Masferrer

134 papers receiving 17.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.

1994 1.3k citations Karen Seibert, K. Leahy et al. Proceedings of the National Academy of Sciences profile →
Nitric oxide activates cyclooxygenase enzymes.

1993 1.2k citations Jaime L. Masferrer, Karen Seibert et al. Proceedings of the National Academy of Sciences profile →
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

1994 1.1k citations Jaime L. Masferrer, Ben S. Zweifel et al. Proceedings of the National Academy of Sciences profile →
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.

2000 1.1k citations Jaime L. Masferrer, K. Leahy et al. PubMed profile →
The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes.

1990 784 citations Jaime L. Masferrer, Karen Seibert et al. profile →
COX-2 is expressed in human pulmonary, colonic, and mammary tumors

2000 745 citations Andrew J. Dannenberg, B. Mark Woerner et al. profile →
Pharmacological analysis of cyclooxygenase-1 in inflammation

1998 713 citations Yan Zhang, Carol M. Koboldt et al. Proceedings of the National Academy of Sciences profile →
Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer.

1999 603 citations Andrew J. Dannenberg, Jaime L. Masferrer et al. PubMed profile →
Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.

1999 602 citations Alane Koki, B. Mark Woerner et al. PubMed profile →
4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2

2000 569 citations John J. Talley, David Brown et al. profile →

Peers

Countries citing papers authored by Jaime L. Masferrer

Since Specialization

Citations

This map shows the geographic impact of Jaime L. Masferrer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaime L. Masferrer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaime L. Masferrer more than expected).

Fields of papers citing papers by Jaime L. Masferrer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaime L. Masferrer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaime L. Masferrer. The network helps show where Jaime L. Masferrer may publish in the future.

Co-authorship network of co-authors of Jaime L. Masferrer

This figure shows the co-authorship network connecting the top 25 collaborators of Jaime L. Masferrer. A scholar is included among the top collaborators of Jaime L. Masferrer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaime L. Masferrer. Jaime L. Masferrer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SGLT2 inhibition potentiates the cardiovascular, renal, and metabolic effects of sGC stimulation in hypertensive rats with prolonged exposure to high-fat diet 2022 ·American Journal of Physiology-Heart and Circulatory Physiology ·Virginia Reverte, Francisca Rodríguez, (unknown), Juan Manuel Moreno, María T. Llinás, Courtney Shea, (unknown), Emmanuel S. Buys, Jaime L. Masferrer, F. Javier Salazar	10
2	Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP/NF-κB/NLRP3 inflammasome circuit 2020 ·Proceedings of the National Academy of Sciences ·Roger Flores‐Costa, Marta Duran‐Güell, Mireia Casulleras, Cristina López‐Vicario, José Alcaraz‐Quiles, Alba Díaz, Juan José Lozano, Esther Titos, K. Hall, Renee Sarno, Jaime L. Masferrer, Joan Clària	45
3	Geldanamycin-Induced PCNA Degradation in Isolated Hsp90 Complex from Cancer Cells 2010 ·Cancer Investigation ·Xing Wang, Deborah M. Heuvelman, James A. Carroll, Dawn Dufield, Jaime L. Masferrer	16
4	Anti‐PDGF‐B monoclonal antibody reduces liver fibrosis development 2010 ·Hepatology Research ·Shinji Ogawa, Takashi Ochi, Hideaki Shimada, (unknown), (unknown), Aisuke Nii, Mark Moffat, Madan Katragadda, Bernard N. Violand, Robert H. Arch, Jaime L. Masferrer	54
5	Pharmacology of PF-4191834, a Novel, Selective Non-Redox 5-Lipoxygenase Inhibitor Effective in Inflammation and Pain 2010 ·Journal of Pharmacology and Experimental Therapeutics ·Jaime L. Masferrer, Ben S. Zweifel, Medora M. Hardy, Gary D. Anderson, Dawn Dufield, Luz Cortes-Burgos, Robert A. Pufahl, Matthew J. Graneto	36
6	CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain 2009 ·European Journal of Pharmacology ·Luz Cortes-Burgos, Ben S. Zweifel, Steven L. Settle, Robert A. Pufahl, Gary D. Anderson, Medora M. Hardy, (unknown), (unknown), (unknown), Zachary S. Stewart, Shanmugam Muthian, Matthew J. Graneto, Jaime L. Masferrer	30
7	Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors 2008 ·European Journal of Pharmacology ·James K. Gierse, Maureen A. Nickols, K. Leahy, (unknown), Yan Zhang, Luz Cortes-Burgos, (unknown), Karen Seibert, Jaime L. Masferrer	28
8	Valdecoxib: Assessment of Cyclooxygenase-2 Potency and Selectivity 2005 ·Journal of Pharmacology and Experimental Therapeutics ·James K. Gierse, Yan Zhang, William F. Hood, Mark C. Walker, Jennifer S. Trigg, Timothy J. Maziasz, Carol M. Koboldt, Jerry Muhammad, Ben S. Zweifel, Jaime L. Masferrer, Peter C. Isakson, Karen Seibert	72
9	The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARγ. Influence of albumin 2004 ·Journal of Hepatology ·Marta López‐Parra, Joan Clària, Esther Titos, Anna Planagumà, Marcelina Párrizas, Jaime L. Masferrer, Wladimiro Jiménez, Vicente Arroyo, Francisca Rivera, Joan Rodés	17
10	Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. 2002 ·PubMed ·Louise R. Howe, Kotha Subbaramaiah, Jay Patel, Jaime L. Masferrer, Aparna Deora, Clifford A. Hudis, Howard T. Thaler, William J. Muller, Baoheng Du, Anthony M.C. Brown, Andrew J. Dannenberg	177
11	Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. 2002 ·PubMed ·Ben S. Zweifel, Thomas W. Davis, Richard Ornberg, Jaime L. Masferrer	125
12	Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. 2002 ·PubMed ·Hussein Abou‐Issa, Galal A. Alshafie, Karen Seibert, Alane Koki, Jaime L. Masferrer, Randall E. Harris	60
13	Cyclooxygenase‐1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites 2002 ·British Journal of Pharmacology ·Marta López‐Parra, Joan Clària, Anna Planagumà, Esther Titos, Jaime L. Masferrer, B. Mark Woerner, Alane Koki, Wladimiro Jiménez, (unknown), Vicente Arroyo, Francisca Rivera, Joan Rodés	35
14	Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. 2000 ·PubMed ·Kazushi Kishi, Sven Petersen, Cordula Petersen, Nancy Hunter, K.A. Mason, Jaime L. Masferrer, Philip J. Tofilon, L. Milas	232
15	4,5-Diaryloxazole inhibitors of cyclooxygenase-2 (COX-2) 1999 ·Medicinal Research Reviews ·John J. Talley, Stephen R. Bertenshaw, David Brown, Jeffery S. Carter, (unknown), Carol M. Koboldt, Jaime L. Masferrer, Bryan H. Norman, D. Joseph Rogier, Ben S. Zweifel, Karen Seibert	32
16	Distribution of Cox-1 and Cox-2 in Normal and Inflamed Tissues 1997 ·Advances in experimental medicine and biology ·Karen Seibert, Yan Zhang, K. Leahy, Scott D. Hauser, Jaime L. Masferrer, Peter C. Isakson	118
17	Pharmacological manipulation of cyclo‐oxygenase‐2 in the inflamed hydronephrotic kidney 1996 ·British Journal of Pharmacology ·Karen Seibert, Jaime L. Masferrer, P Needleman, Daniela Salvemini	32
18	[2] Interactions of nitric oxide with cyclooxygenase: In vitro, ex vivo, and in vivo studies 1996 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Daniela Salvemini, Jaime L. Masferrer	78
19	Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. 1996 ·The Journal of Experimental Medicine ·Joseph P. Portanova, (unknown), Graham Anderson, Scott D. Hauser, Jaime L. Masferrer, Karen Seibert, S A Gregory, Peter C. Isakson	359
20	Cytochrome P450 arachidonic acid metabolism in bovine corneal epithelium 1986 ·Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States) ·Jaime L. Masferrer, Michal L. Schwartzman, Nader G. Abraham, Michael W. Dunn, J C McGiff	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact